Wird geladen...
Requiring an amyloid-β(1-42) biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials
BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-β(1-42) concentration and high total-tau/Aβ(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer’s disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials. M...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2010
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2947209/ https://ncbi.nlm.nih.gov/pubmed/20813339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2010.07.004 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|